Breaking Finance News

Esperion Therapeutics, Inc. (NASDAQ: ESPR) Shares Soar

Esperion-TherapeuticsShares of Esperion Therapeutics, Inc. (NASDAQ: ESPR) surged to $28.70 per share, up 17.53% from yesterday’s closing trade of $24.42, this after announcing its high cholesterol drug achieved trial goals. For the past 52 weeks, trading ranged between $10.90 and $30.00 per share.

Esperion reported positive results from its clinical trial of the experimental high-cholesterol drug ETC-1002. Trial results showed patients treated with ETC-1002 had more significant reductions in levels of LDL “bad” cholesterol compared to patients who took Zetia, manufactured by Merck & Co. (NYSE: MRK).

The 12-week clinical trial consisted of 348 patients with high levels of cholesterol. Patients given a smaller dose of ETC-1002 (120 milligrams) had a 27% reduction in bad cholesterol and for those administered a larger dose (180 milligrams), reduction rate increased to 30%. However, patients given a small dose of both ETC-1002 and Zetia (10 milligrams) experienced an impressive 43% reduction in LDL cholesterol.

The study used a comparison of ETC-1002 to Zetia in patients with or without statin intolerance. The two-drug combination was successful in reducing high levels of bad cholesterol but also certain types of inflammation specific to coronary disease. Researchers noted significant reductions within the first two weeks of dosing, as well as throughout the remainder of the study.

Esperion Therapeutics, Inc. is a clinical-stage biopharmaceutical company that focuses on research, development, and commercialization of low-density oral lipoprotein cholesterol-lowering therapies for patients with high LDL cholesterol levels, as well as other cardiometabolic risk markers.

ETC-1002 is designed as an oral molecule therapy to treat carbohydrate and lipid metabolic pathways. Two other Esperion drugs are in pre-clinical trials to include ESP41091 for patients with obesity and type 2 diabetes, and 4WF, a synthetic apoA-1 therapy for patients with acute coronary syndrome.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.